Dublin, Aug. 25, 2016 -- Research and Markets has announced the addition of the "Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2025" report to their offering.
Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2025 examines the leaders in the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts based recent market conditions.
For each company covered, the report provides:
- Corporate Summary
- Total Company Revenue and Total R&D Spending 2011-2015
- Break-up of Sales by Region, 2015
- Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
- Pharmaceutical Segment Sales, 2011 through 2015 and Forecasted 2025
- Leading Pharmaceutical Products, 2015 Sales
- Late Stage Product Pipeline
- Late Stage Product Pipeline by Therapeutic Area, Comparing 2009, 2011, 2013 and 2015
- Corporate Development Details
The companies covered in this study include:
- Pfizer
- Novartis
- Roche
- Merck
- Sanofi and 20 more
Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2025 provides a thorough discussion of current trends in pharmaceutical research and development, including:
- Pharmaceutical Research & Development Challenge
- The Drug Approval Process
- Expanded Options in Treating Diseases
- Biotechnology Drug Development
- Orphan Drugs
- Fast Track Drug Status
- Other Accelerated Methods for Drug Approval
- Pharmaceutical Regulatory Exclusivity
- The Role of Contract Research Organizations
In addition to its company focus, the report examines the global pharmaceutical market, which has continued its recovery from the economic downfall experienced in recent years. Healthcare costs as a percent of GDP are increasing in almost all countries, though there are some exceptions. There are a number of macroeconomic concerns affecting sales such as aging populations, incidence of disease, unmet medical needs, government activities, and more.
Data provided include:
- Global Pharmaceutical Projects in Development by Therapeutic Segment
- Global Pharmaceutical Market, 2011-2015 and Forecasted 2025
- Global Pharmaceutical Market by Therapeutic Area, 2011-2015 and Forecasted 2025
- Total Healthcare Expenditures as a Percent of GDP by Country 2010 and 2015 Estimates (Australia, Austria, Canada, Czech Republic, Finland, France, Germany, Greece, Italy, Japan, Mexico, Switzerland, United Kingdom, United States)
- International Population Trend Age 65+
For more information about this report visit http://www.researchandmarkets.com/research/5tjnq3/top_25
Related Topics: Pharmaceuticals
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


China Vanke Seeks Bond Extension Amid Mounting Debt Crisis
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 



